No prior tweaking was possible. The data wasn't available to anybody before it was given to the independent statistician because it had been gathered as part of a double-blind predictive trial and had not been unblinded yet. So basically nobody knew what the results would be. The company took a gamble.
"The testing failed but wait...if RAP and Pfizer were aware that the Covid test required further testing and then had to be sent for approval" – you can't apply for approval without a clinical trial to prove your claims. The data that was unblinded and given to the statistician would have been gathered for that purpose. I think you may have joined dots that are just a bit too far apart in this case.
By unblinding and testing partway through the trial this data is effectively ruined for approval purposes. That trial will have to be extended now to gather enough data for approval. The upside is that now the algorithm can be retrained and there is a better chance of meeting the thresholds required by the regulators.
We just need to vote the takeover down in order to get the benefit.
RAP Price at posting:
12.0¢ Sentiment: Hold Disclosure: Held
